DANIEL IBRAHIM

Group Leader Genetics & Rare Diseases | Nominee Non-Voting Member

Scientific Development/ CV:

since 04/2020	PI BCRT – Crossfield GenoPro Focus: Extending the interpretable genome
since 07/2018	Postdoc BCRT – Crossfield GenoPro Focus: Functional characterization of TADs in developmental gene regulation
2014 – 2018Postdoc	Berlin Institute of Health (Project Leaders: Mundlos/Pombo) Focus: Mis-regulated chromatin folding as a cause of congenital disease
2009 – 2014	PhD BSRT & MPI Molecular Genetics (Advisor: Hecht/Mundlos) Project: Characterization of disease-causing transcription factor mutations using ChIP-seq

Expertise:

- Molecular pathomechanisms underlying rare diseases
- Gene regulation and developmental biology
- Chromatin biology
- Functional genomics
- Genome engineering

Relevant Projects/ Highlights:

- Determining the regulatory genome in disease-relevant cell types of the skeleton
- The role of 3D chromatin structure on gene regulation and disease
- Synthetic Biology in mammalian cells

DANIEL IBRAHIM

Group Leader Genetics & Rare Diseases | Nominee Non-Voting Member

Objectives for the BCRT

I see the BCRT as a hub where cutting-edge research can be directly translated into patient care and where clinical need and observations from the clinic inform the scientific questions in research programs.

On the (basic) research end of this pipeline, our knowledge of how the genome controls cell fate and differentiation can be used as a key technology to characterise cell types and optimize cell differentiation protocols.
As trained basic researcher, I know about the limitations of broadly used model systems. Instead, observations and challenges from applied and translated cell products provide exciting “real-life” problems that can inform new research questions.

I believe that a tightly linked interdisciplinary exchange between clinicians, basic and applied researchers can produce the best translational environment.